Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Researchers who work with tiny drug carriers known as lipid nanoparticles have developed a new type of material capable of reaching the lungs and the eyes, an important step toward genetic therapy for hereditary conditions like inherited vision loss.
Researchers have discovered profound similarities and surprising differences between humans and insects in the production of the critical light-absorbing molecule of the retina, 11-cis-retinal, also known as the “visual chromophore.”
In a new study, researchers conducted a comprehensive study that uncovered key genes, biological processes and cell types that may affect the pathogenesis of primary open angle glaucoma, in intraocular pressure-dependent and independent manners.
Neuroscientists at Johns Hopkins Medicine have shown that intrinsically-photosensitive retinal ganglion cells use two different pathways at the same time to transmit electrical “vision” signals to the brain.
NEI researchers improved a crucial step in the production of retinal pigment epithelium (RPE), a tissue they grow in the lab from patient blood cells and are testing in a clinical trial as treatment for AMD.
By adapting virus-like particles to carry the machinery for a type of gene editing called prime editing, scientists have corrected disease-causing mutations in animals and increased editing efficiency.
Researchers at Indiana University School of Medicine are using a novel approach to hopefully develop a new therapy for glaucoma, a complex disease that eventually leads to blindness.
A team of scientists have received funding to explore new approaches to disentangle intricate nerve networks in the cornea and discover which nerve makes people blink, which creates tears and which nerve tells us our eye is in pain.